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Abstract 
Nuclear imaging used in diagnostic medicine requires the use of 
radiopharmaceuticals to make biological areas visible under a gamma camera. 
Although much success has been found in the use of technetium based imaging 
agents, their corresponding rhenium complexes can provide insight into the 
chemical properties of these radiopharmaceuticals without the potentially 
damaging effects of radiation. Technetium and rhenium complexes utilize a 
bifunctional chelator to act as a linker between biological vectors and the metal, 
improving the coordination between the two. Ligands containing thiazole rings 
have been successfully coordinated to technetium or rhenium tricarbonyl 
complexes, although it is uncertain whether coordination occurs through the 
nitrogen or the sulfur of the thiazole ring. Imaging studies of isomers of these 
compounds have extended understanding of the functioning of these compounds 
by providing insight into the chemistry of their coordination.  
 
This project involves the study of [Re(CO)3-1,1-bisthiazolate-(1,4)-
diaminobutane] as a surrogate for the technetium based complex. The precursor to 
this complex, N1,N1-bis(thiazol-2, 4, or 5-ylmethyl)butane-1,4-diamine has been 
successfully synthesized using thiazole ring containing isomers, thiazole-2-
carboxaldehyde, thiazole-4-carboxaldehyde, and thiazole-5-carboxaldehyde. 
Reverse-phase high performance liquid chromatography and characterization 
through 
1
H-Nuclear Magnetic Resonance (
1
H-NMR) and Electrospray Ionization-
Mass Spectrometry (ESI-MS) have been completed to purify and confirm the 
presence of the desired products.  
 
HPLC chromatograms for N1,N1-bis(thiazol-2,4, or 5-ylmethyl)butane-
1,4-diamine synthesized with thiazole-2-carboxaldehyde, thiazole-4-
carboxaldehyde, or thiazole-5-carboxaldehyde give singular peaks indicating 
significant ligand purity and relatively poor yield. Following purification, it was 
determined that the solvent was best removed by lyophilization to minimize the 
deterioration of the product. 
1
H-NMR and ESI-MS results confirm the presence of 
the product, indicating that the desired ligands have been successfully 
synthesized.  
 
Additional research requires more extensive characterization of the 
synthesized ligands before the synthesis of the final product using these ligands. 
Previous research indicates that this product has a high potential for use as 
fluorescent surrogates to the corresponding technetium complexes. Fluorescence 
tests on the rhenium complexes should provide insight on the nature of the 
coordination of rhenium to the chelate and biological vectors. Extensive in vitro 
and in vivo studies will require completion before these complexes can be used in 
a clinical setting.  
2 
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Executive Summary  
Nuclear imaging techniques, such as single photon emission computed 
tomography (SPECT) and positron emission tomography (PET), used in 
diagnostic medicine, require the use of radiopharmaceuticals (radioactive 
pharmaceuticals) to make biological areas visible. These radiopharmaceuticals are 
used as tracers that tag the biological areas, making them visible under a camera 
that detects the gamma rays emitted from the radiopharmaceuticals. Because 
radioactive substances are damaging to cells and biological tissues, the ideal 
imaging agent selectively targets the area to be imaged and is effective in that it is 
removed efficiently from the body to minimize harm. A number of 
radiopharmaceuticals are based on the radioactive transition metal, technetium. 
This metal has a half-life of six hours, which gives sufficient time for preparation, 
cellular absorption, imaging, and elimination of agent.  
 
Although much success has been found in the use of technetium based 
imaging agents, their corresponding rhenium complexes can provide insight into 
the chemical properties of these radiopharmaceuticals without the potentially 
damaging effects of radiation. Rhenium is not radioactive, but emits fluorescent 
light, which eliminates the cell damage caused by radioactive substances while 
still allowing the imaging of cells. The chemical and photochemical properties of 
rhenium are comparable to those of technetium, making it a valid fluorescent 
surrogate for the radioactive metal.  
 
4 
Technetium and rhenium imaging agents utilize a bifunctional chelator to act as a 
linker between biological vectors (proteins) and the metal (technetium or 
rhenium), improving the coordination between the two. Bifunctional refers to the 
two places for binding, one for the biological vector and the other for the metal, 
on the chelate, which is simply an ion or molecule that binds metal ions.  
 
Ligands are molecules that bind to a central metal atom to form a 
coordination complex. Thiazole ring containing ligands include a nitrogen and a 
sulfur atom in the ring and have been successfully coordinated to technetium or 
rhenium tricarbonyl ((CO)3) complexes. However, it is uncertain whether the 
connection to the metal occurs through the nitrogen or the sulfur of the thiazole 
ring. Imaging studies of isomers, structures with the same chemical formula but 
different attachments between atoms, of these compounds containing thiazole 
rings have extended understanding of the functioning of bifunctional chelates by 
providing insight into the chemistry of their coordination.  
 
This project involves the study of  [Re(CO)3-1,1-bisthiazole-(1,4)-
diaminobutane] as a fluorescent surrogate for the technetium based complex. This 
complex contains a tricarbonyl core bound to rhenium, which is also bound to a 
thiazole ligand. The precursor to this complex, N1,N1-bis(thiazol-2, 4, or 5-
ylmethyl)butane-1,4-diamine has been successfully synthesized using thiazole 
ring containing isomers, thiazole-2-carboxaldehyde, thiazole-4-carboxaldehyde, 
and thiazole-5-carboxaldehyde, which vary in the placement of the nitrogen and 
5 
sulfur atoms in the thiazole ring. Reverse-phase high performance liquid 
chromatography (HPLC) and characterization through 
1
H-NMR and (ESI-MS) 
have been completed to purify and confirm the presence of the desired products.  
 
HPLC separates the components of a mixture by passing them through a 
column filled with absorbent material, in this case, a silica resin. Because of their 
different chemical properties, specifically polarity and hydrophobicity, each 
component of the mixture is absorbed at different times, affecting when they flow 
out of the column. In polar compounds, the electrons on atoms are shared 
unequally, creating slight positive and negative charges where the electrons are 
given or taken. Polar molecules tend to be hydrophilic and are attracted to water, 
while nonpolar molecules are hydrophobic and are repelled by water. Hydrophilic 
molecules are attracted to the column and are left stationary for longer periods 
than hydrophobic molecules that are repelled by the column and pass through 
easily at a quicker rate. The components first appearing in the chromatogram are 
more hydrophobic and nonpolar than those appearing later.  
 
HPLC produces chromatograms, which display a series of peaks that vary 
in time and integration. Each peak corresponds to a different component of the 
mixture with the integration of the peak related to the amount of the component 
present in the mixture. The larger the integration of the peak, the more pure a 
component is. HPLC chromatograms for N1,N1-bis(thiazol-2,4, or 5-
ylmethyl)butane-1,4-diamine synthesized with thiazole-2-carboxaldehyde, 
6 
thiazole-4-carboxaldehyde, or thiazole-5-carboxaldehyde give singular peaks with 
significant integration, indicating significant ligand purity of reasonable yield.  
 
Following purification, it was determined that the solvent was best 
removed by lyophilization to minimize the deterioration of the product. Heating 
caused by removal of the solvent in a vacuum deteriorated the product. 
Lyophilization freeze-dries the product, eliminating the loss of product to heat.  
 
1
H-NMR studies interactions between the nuclei of hydrogens as 
described by their magnetic properties. 
1
H-NMR spectra display peaks of varying 
integrations and chemical shifts. The integrations of the peaks correspond to the 
number of identical hydrogens that the peak represents, while chemical shift 
describes the surrounding environment of the hydrogens giving information about 
the number and types of neighboring hydrogens. Chemical shift is most affected 
functional groups nearest to the hydrogens. These groups adjust the electron 
density of the hydrogen, either donating or withdrawing electrons. Donating 
groups tend to increase shielding, while withdrawing groups decrease shielding. 
Shielding refers to when a magnetic field is induced around the hydrogen in 
opposition to the magnetic field applied to the sample. This effect decreases the 
chemical shift, moving the peak upfield on the spectra. The opposite is observed 
for deshielding. The trends in chemical shifts are used to interpret 
1
H-NMR 
spectra and confirm the presence of product.  
 
7 
ESI-MS measures the mass of ion fragments from a molecule. Certain 
fragments are commonly observed, making the determination of the molecular 
mass straightforward. ESI-MS results gave an m/z peak at 283 for N1,N1-
bis(thiazol-2-ylmethyl)butane-1,4-diamine. The m/z peak represents the mass of 
the compound plus one with the one most likely coming from positively charged 
hydrogen, resulting from the ionization of the sample. The mass of N1,N1-
bis(thiazol-2-ylmethyl)butane-1,4-diamine is 282, indicating that the desired 
ligands have been successfully synthesized.  
 
Additional research on these rhenium compounds requires more extensive 
characterization of the synthesized ligands before the synthesis of the final 
product using these ligands. These additional characterization methods would 
confirm the presence of products by focusing on the examination of their various 
chemical properties. Previous research indicates that the overall product, 
[Re(CO)3-1,1-bisthiazolate-(1,4)-diaminobutane], has a high potential for use as a 
fluorescent surrogate to the corresponding technetium complexes. Tests 
examining the fluorescence of the rhenium complexes synthesized using the 
different ligands should provide insight on the nature of the coordination of 
rhenium to the chelate and eventually, to cells. Extensive studies in cells both 
outside and inside the body will require completion before these complexes can 
be used in a clinical setting. 
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Chapter 1: Introduction 
 
Background 
Within the medical field, the detection and diagnosis of disease often 
requires the use of imaging and scanning through diagnostic nuclear imaging 
techniques to provide rapid, noninvasive results. The use of these methods 
promotes early detection and treatment, improving the prognosis of a disease 
before it progresses to later stages, and ultimately lowering the cost to the patient. 
In targeting particular areas, treatments can be specified to the required areas, 
minimizing side effects and complications.
1
 
 
Medicine utilizes two main imaging techniques, SPECT) and PET.
1
 
Although both techniques function similarly, utilizing gamma cameras to detect 
gamma rays emitted from radioactive isotopes injected into the patient, they each 
have their own advantages and disadvantages.
1
 While PET offers higher 
resolution images, SPECT utilizes more readily available, longer-lived, and 
cheaper radioactive isotopes, including 
123
I, 
111
In, and 
99m
Tc.
1-5
 The ideal imaging 
agent is effective and selective and ideally improves staging, prognosis, and post-
therapy monitoring. Of the commonly used isotopes, 
99m
Tc is often preferred.
1-5
 
 
Technetium-99m is an isomer of the radioactive transition metal, 
technetium, and has successfully been used as a radioactive tracer for medical 
imaging.
6
 It emits gamma rays at an ideal energy, 140-keV, for use with the 
10 
gamma cameras utilized in SPECT and PET imaging.
1
 Additionally, 
99m
Tc has a 
half-life of six hours, making it an ideal candidate for use in medical imaging as 
this length allows sufficient time for on-site preparation and accumulation in the 
target tissue while reducing the amount of radiation exposure to the patient.
6
 The 
low radiation dose provided by 
99m
Tc also causes low amounts of tissue damage 
compared to other isotopes.
7
 
99m
Tc can be prepared in on-site generators in 
radiopharmacies in the form of a pertechnetate, Na
99m
TcO4, with high specific 
activity, ideal for its use as a molecular imaging agent.
8
  
 
Unfortunately, because 
99m
Tc is a transition metal, it produces unstable 
products when substituted in a targeting vector since it cannot be directly 
substituted for a hydrogen atom.
9
 The coordination of technetium to suitable 
ligands has offered a solution to this problem and has allowed the successful 
incorporation of technetium into complexes used as molecular imaging 
probes.
1,6,7,10
  
 
Technetium radiopharmaceuticals are divided into two categories based on 
the method of technetium incorporation: technetium-essential or technetium-
tagged compounds.
7
 In technetium-essential compounds, technetium is 
incorporated into the targeting vector, directly contributing to the structure and 
overall physicochemical properties of the molecule.
11
 Examples include those 
shown in figures 1 and 2, which are used in heart imaging and brain imaging 
respectively.
12,13
  
11 
 
Figure 1. The chemical structure of the technetium-essential heart-imaging agent, 
Cardiolite.
12
 
 
 
Figure 2. The chemical structure of the technetium-essential brain-imaging agent, 
[TcO(hexamethylpropylene amine oxide)].
13
  
 
These complexes are useful in the targeting of phagocytosis, hepatocyte 
clearance, glomerular filtration, bone sorption, and other high capacity systems.
1
 
Distribution in the body is dictated by blood flow and the complexes tend to have 
low molecular weights.
7
  
 
Technetium-tagged complexes involve the carrying of the technetium 
atom by the target vector, indicating that the functioning of the biological target 
does not depend on the incorporation of the technetium atom.
1,7,11
 Biodistribution 
of this class targets low capacity systems that rely on specific enzymatic or 
12 
receptor binding interactions.
7
 The technetium atom is incorporated through 
integration or conjugation.
1,11
 Integration allows the retention of binding affinity 
through the replacement of a receptor ligand with a technetium chelator.
1,11
 
Conjugation tethers a 
99m
Tc-moiety to a molecule that exhibits high affinity 
binding to a receptor.
1,11
 In this method, single amino acid chelates are often used 
to link radioactive metal cations to a biologically active molecule (see figure 
3).
1,7,11
  
 
 
Figure 3. A depiction of how a bifunctional chelate attaches to a radionuclide 
(metal, technetium-99m) and a biological vector.
1
 
 
Because it is a transition metal, 
99m
Tc produces an unstable compound 
upon direct substitution into a target vector, complicating its labeling chemistry, 
and limiting its usefulness.
1,7,10
 Fortunately, the use of single amino acid chelates 
eliminates this complication. The chelator serves as a connection between the 
radioactive metal and the biological vector by binding to 
99m
Tc at one site and 
binding to the target vector at a separate site.
1,7,10
 The chelate also securely binds 
the metal radionuclide to prevent leakage in vivo, while retaining a functional site 
for connection to the target vector.
1
 A {Tc(CO)3}
+
 core binds to a bifunctional 
chelate for incorporation into peptide-based targeting vectors.
7,9
 The addition of 
13 
the bifunctional chelate to the radionuclide is essential as it prevents dissociation 
of the complex by securely binding to a fac-metal core and maintaining the 
integrity of the biomolecular structure.
1,7,9
 The coordination chemistry of this 
radioactive 
99m
Tc tricarbonyl core has been further studied using its non-
radioactive congener, rhenium.  
 
As an alternative, rhenium makes possible the synthesis of a metallo-
labeled conjugate while limiting the presence of radioactive isotopes.
1-15
 Rhenium 
exhibits fluorescence, allowing study of the chelate system to occur at subcellular 
level before testing in living subjects.
1,6
 Additionally, combining this rhenium-
based core to a bisthiazole ligand helps produce a stable octahedral complex by 
facially chelating the Re-fac tricarbonyl core through its nitrogen in the amine and 
thiazole rings, to the biological vectors.
14,15
 This method of chelation increases the 
stability of the compound through σ and π donating from the amine and thiazole 
rings and allows for the ease of conjugation to the biological vectors.
1
 The 
nitrogen atom donates electrons that promote the formation of the appropriate 
geometry, while the amine nitrogen provides the electrons that allow the link to 
the biological vector (a peptide).
1,14
  
 
The thiazole ring allows coordination to isomers through the donation of 
electrons offered by sulfur or nitrogen. Coordination through thiazole nitrogen is 
more common as this is a better donor than sulfur. Computational calculations 
indicate, however, that coordination through the sulfur of one or both thiazole 
14 
rings to rhenium does produce a stable structure. Changes in coordination affect 
the chemical properties of these complexes including their stability and 
luminescent properties. Further exploration of the nature of the coordination 
occurring in rhenium based metallo-labeled conjugates can expand understanding 
on the functioning of these complexes and have the potential to produce a 
complex with favorable fluorescent properties. As nonradioactive surrogates, the 
structure and understanding of the properties of these rhenium complexes can 
then be applied to further understand and study their radioactive technetium 
counterparts.
14
  
 
Ligand Variation 
There has been previous success synthesizing [Re(CO)3-1,1-bisthiazolate-
(1,4)-diaminobutane] (P1) using thiazole-4-carboxaldehyde (T4) (figures 4 and 5 
respectively).
14
 This project successfully utilized isomers of thiazole-4-
carboxaldehyde, thiazole-2-carboxaldehyde (T2) and thiazole-5-carboxaldehyde 
(T5), to synthesize the precursor, N1,N1-bis(thiazol-4-ylmethyl)butane-1,4-
diamine (L4) (figures 6 though 8 respectively). Synthesized with T2 or T5, this 
precursor becomes N1,N1-bis(thiazol-2-ylmethyl)butane-1,4-diamine (L2) or 
N1,N1-bis(thiazol-5-ylmethyl)butane-1,4-diamine (L5).  
 
 
15 
 
Figure 4. The structure of [Re(CO)3-1,1-bisthiazolate-(1,4)-diaminobutane] (P1).  
 
Figure 5. The structure of thiazole-4-carboxaldehyde (T4). 
 
 
Figure 6. The structure of thiazole-2-carboxaldehyde (T2). 
 
 
Figure 7. The structure of thiazole-5-carboxaldehyde (T5). 
 
16 
 
Figure 8. The structure of N1,N1-bis(thiazol-4-ylmethyl)butane-1,4-diamine (L4). 
Synthesis of this compound with T2 or T5 adjusts the placement of the nitrogen 
and sulfur on the thiazole ring.  
 
The expectation is that rhenium complexes synthesized with these isomers 
will provide greater insight into the chemistry of the coordination of rhenium 
complexes and that the synthesized compound will exhibit greater fluorescence. 
Based on previous research, it is strongly suggested that these rhenium complexes 
can indeed served as fluorescent, nonradioactive surrogates of technetium based 
complexes for future use in nuclear imaging.
14
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Chapter 2: Method 
 
Completion of this project rests on the synthesis of P1 using T2, T4, and 
T5 (see scheme 1).  
 
 
Scheme 1. Synthesis of P1.   
 
This synthesis requires a three-part reaction, the first of which has been 
successfully synthesized the ligand, L2, L4, and L5, using the respective isomers 
of thiazole-carboxaldehyde. The ligands were synthesized using T2, T4, and T5 
according to the methods described below.  
 
Synthesis of N1,N1-bis(thiazol-2, 4, or 5-ylmethyl)butane-1,4-diamine 
(L2, L4, or L5) 
According to the process described by Henry et al., synthesis of the 
rhenium complex, P1, begins with the initial formation of the ligand, 1,1-
bisthiazolate-(1,4)-diaminobutane.
14
 The synthetic scheme of this ligand can be 
viewed in Scheme 2.  
 
18 
 
Scheme 2. Synthesis of 1,1-bisthiazole-(1,4)-diaminobutane ligand involving the 
combination of N-BOC-1,4-butanediamine and thiazole-4-carboxaldehyde to give 
1,1-bisthiazolate-1,4-diaminobutane after the removal of the BOC protecting 
group. 
 
This synthesis began by mixing N-Boc-1,4-butanediamine (300 mg, 1.5 
mmol) and T2, T4, or T5 (360 mg, 3.0 mmol) in dichloroethane (DCE) under 
nitrogen gas at room temperature. After 30 minutes, sodium 
triacetoxyborohydride (954 mg, 3.0 mmol) was added to the mixture with 
additional DCE and was stirred for 16 hours. Then, the solvent was removed in 
vacuo to give an oily product that was mustard yellow to dark amber in color. The 
product was dissolved in a mixture of 10% methanol and 10% trifluoracetic acid 
in water and was stirred for 3 hours. The product was a light yellow liquid. From 
there, the ligand, 1,1-bisthiazolate-(1,4)-diaminobutane, was purified using 
reverse-phase HPLC with a gradient of 100% 0.1% TFA in water increased to 
20% acetonitrile (MeCN) over 5 minutes, and increased to 40% MeCN over 2.5 
19 
minutes, and increased to 100% MeCN over 2.5 minutes. HPLC purification 
resulted in a clear liquid.  
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Chapter 3: Characterization Results 
 
The products synthesized at each step were characterized using various 
methods. Nuclear magnetic resonance (NMR) spectra were obtained using a 
Bruker Advance DPX 300 MHz spectrometer. High Performance Liquid 
Chromatography chromatograms were obtained using an Agilent 1200 reverse-
phase HPLC instrument with a manual injector and automated fraction collector. 
Electrospray ionization-mass spectra (ESI-MS) were obtained using a Shimadzu 
2000 Electrospray Ionization Mass Spectrometer. Additional characterization 
methods to be performed in future endeavors are listed in Chapter 4: Anticipated 
Characterization.  
 
1
H-Nuclear Magnetic Resonance (NMR) of Crude Ligands 
The 
1
H-Nuclear Magnetic Resonance spectra of L2 and L5 were obtained 
before the samples were purified by HPLC. The spectra correlate to figures 9 and 
10 respectively.  
 
21 
 
Figure 9. 
1
H-NMR spectra of crude of L2. The NH2 peak appears at 
approximately 4.8 ppm with impurities from methanol and trifluoroacetic acid at 
approximately 3.5 ppm and 8.8 ppm respectively.  
 
 
Figure 10. 
1
H-NMR spectra of crude L5. The NH2 peak appears at approximately 
4.8 ppm, while impurities from methanol appear at approximately 3.3 ppm.  
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Solubility Tests 
Solubility tests were performed on the crude L2 and L5 to determine an 
ideal method for purification. Water, methanol, acetonitrile, toluene, acetone, 
chloroform, pyridine, pentane, dichloromethane (DCM), hexane, ethyl acetate, 
butanol, tetrahydrofuran (THF), 2-propanol, and diethyl ether were tested. Both 
ligands exhibited solubility in only water, methanol, acetone, pyridine, and ethyl 
acetate, and neither were soluble in acetonitrile. There does not appear to be a 
correlation between the solubility of the ligands and solvent polarity. The results 
may be viewed in chart 1.  
 
Solvent Crude L2 Crude L5 
H2O Soluble Soluble 
Methanol Soluble Soluble 
Acetonitrile Insoluble Insoluble 
Toluene Insoluble Insoluble 
Acetone Soluble Soluble 
Chloroform Insoluble Insoluble 
Pyridine Soluble Soluble 
Pentane Insoluble Insoluble 
Dichloromethane Insoluble Insoluble 
Hexane Insoluble Insoluble 
Ethyl Acetate Soluble Soluble 
Butanol Insoluble Insoluble 
THF Insoluble Insoluble 
2-propanol Insoluble Insoluble 
Diethyl Ether Insoluble Insoluble 
 
Chart 1. The results of solubility tests performed on crude L2 and L5 using a 
variety of solvents. 
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Thin Layer Chromatography (TLC) 
Thin Layer Chromatography was performed on the crude L2 and L5 
ligands, N-Boc-butane-1,4-diamine, T2, and T5 to explore the possibility of 
performing normal phase-HPLC. All samples were dissolved in methanol and 
eluted with acetone to promote clear separation on the TLC plates. Two Rf values 
were calculated for the ligand sample at 0 and approximately 0.778, with the 
value at 0 corresponding to the ligand. The spots at 0.778 indicate a synthetic 
impurity, as would be expected for the crude ligands. Based on the Rf values for 
T2 and T5, it can be concluded that the spots at 0.778 are not due to remaining 
starting material. Because the lack of mobility displayed by the ligand, normal-
phase HPLC was eliminated as a possible purification method. The Rf values 
calculated for each sample can be viewed in chart 2. 
 
Compound Rf values 
L2 0 and 0.786 
L5 0 and 0.773 
N-Boc-butane-1,4-diamine 0.702 
T2 0.869 
T5 0.940 
 
Chart 2. Rf values calculated for samples dissolved in methanol and eluted with 
acetone.  
 
Reverse Phase High-Performance Liquid Chromatography (HPLC) 
Reverse Phase High-Performance Liquid Chromatography was performed 
to purify L2, L4, and L5 according to the procedures outlined above in the 
Synthesis of N1,N1-bis(thiazol-2, 4, or 5-ylmethyl)butane-1,4-diamine (L2, L4, 
24 
L5) section of Chapter 2: Method. The HPLC chromatograms for the 
experimentally synthesized and purified ligands can be viewed in figures 11, 12, 
and 13 respectively. L2 gives a singular peak at 8.779 minutes, indicating 
significant ligand purity. L4 shows peaks at 4.534 and 5.738 minutes, indicating 
the significant presence of two components. Based on the intensity of the peaks, 
the peak at 5.738 minutes corresponds to pure L4. L5 shows the presence of 
several components, with the peak at 5.675 minutes having the greatest intensity 
and corresponding to pure L5. 
 
 
Figure 11. HPLC chromatogram obtained for the purification of L2. HPLC was 
performed with the parameters of 100% 0.10% trifluoroacetic acid in water and 
0% methanol to 75% methanol over ten minutes and then increased to 100% 
methanol over two minutes.  
 
25 
 
Figure 12. HPLC chromatogram obtained for the purification of L4. HPLC was 
performed with the parameters of 100% 0.10% trifluoroacetic acid in water and 
0% acetonitrile to 20% acetonitrile over 7.5 minutes and then increased to 40% 
acetonitrile over 2.5 minutes, and then to 100% acetonitrile over 2.5 minutes with 
a two minutes hold.  
 
 
Figure 13. HPLC chromatogram obtained for the purification of L5. HPLC was 
performed with the parameters of 100% 0.10% trifluoroacetic acid in water to 
20% methanol over five minutes with a two minute hold, and then increased to 
40% methanol over 2.5 minutes, and finally to 100% methanol over 2.5 minutes.  
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1
H-NMR of Pure Ligands 
1
H-NMR results showed that the desired produce was being deteriorated 
from the heat produced in the process of solvent removal in vacuo (see figure 14). 
To prevent deterioration, lyophilization was used instead. The freezing methods 
utilized in this process eliminate the heat causing the deterioration of product and 
is a less damaging way of removing solvent. This method also eliminates the 
bumping observed in in vacuo solvent removal processes, maximizing the amount 
of product obtained. The spectra for L2 and L4 following lyophilization can be 
seen in figures 15 and 16 respectively. L5 appears to be less stable and showed a 
lack of product in its 
1
H-NMR spectra.  
 
 
Figure 14. 
1
H-NMR spectra of L2 following the removal of solvent in vacuo. The 
spectrum indicates product deterioration due to the heat produced by this solvent 
removal method. There is a lack of NH2 peak in the 4 to 5 ppm range, indicating 
the lack of product. The peak at 3.6 ppm corresponds to methanol. 
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Figure 15. 
1
H-NMR spectrum of L2 following the removal of solvent through 
lyophilization. The spectrum shows minimal product deterioration and a slight 
impurity attributed to methanol. The peak at 5.8 ppm is attributed to NH2 and 
confirms the presence of the L2. The methanol impurity is observed at 3.3 ppm. 
 
 
Figure 16. 
1
H-NMR spectrum L5 following the removal of solvent through 
lyophilization. The spectrum indicates minimal product deterioration. The NH2 
peaks of L5 appear at 4.8 ppm and the peak at 3.4 ppm can be attributed to a 
slight impurity from methanol.  
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Electrospray Ionization-Mass Spectrometry (ESI-MS) 
Electrospray Ionization-Mass Spectroscopy (ESI-MS) of L2 indicates an 
m/z peak at 283 and may be seen in figure 16. The m/z peak appears where 
expected as L2 has a molecular weight of 282 grams, confirming the presence of 
the product. 
 
 
Figure 17.  ESI-MS of L2 indicating an m/z peak at 283.  
 
Crystallization Studies 
Crude samples of the ligands synthesized with each isomer and 
[Re(H2O)3(CO)3]
+
Br
-
 and were refluxed at temperatures greater than 65°C for 3 
hours in methanol. A variety of slow evaporation and solvent diffusion techniques 
were tested. Samples were dissolved in methanol or dichloromethane and allowed 
to evaporate slowly. Diffusion techniques included the use of methanol/ether and 
acetonitrile/isopropyl alcohol. Unfortunately, the lack of crystal products suggests 
that the ligands need additional purification due to their oily nature.  
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Chapter 4: Future Research 
 
Based on previous research results, P1 synthesized using L2, L4, and L5 
show high potential for their use as fluorescent surrogates for the corresponding 
technetium complexes.
14
 Before the final product can be synthesized however, the 
purified ligands require additional characterization. The final product will also 
require purification and extensive characterization, including fluorescence tests, to 
provide insight on the nature of the coordination to the chelate and biological 
vectors. Beyond this, extensive clinical studies need to be completed before the 
information gained can be applied to radioactive technetium complexes for 
practical use as nuclear imaging agents.  
 
Further Synthesis 
Continuation of this project first requires the synthesis of the final product, 
[Re(CO)3-1,1-bisthiazolate-(1,4)-diaminobutane] (P1), using the ligands 
synthesized using T2, T4, and T5 by the methods described by Henry et al.
14
 This 
procedure entails the synthesis of Re(H2O)3(CO)3, which is then coupled with the 
ligand, L2, L4, or L5, to create the final product. Additional research needs to be 
done on the purification method to find a better way of purifying the ligands by 
minimizing the deterioration and maximizing product yield.  
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Additional Characterization 
Characterization of the products created at each step of the synthesis 
(thiazole ligands (L2, L4, and L5), rhenium compound, and P1 synthesized with 
L2, L4, and L5) requires further attention. 
1
H-NMR and mass spectrometry in the 
form of ESI-MS and/or Matrix-Assisted Laser Desorption/Ionization Time-of-
Flight Mass Spectrometry (MALDI ToF MS) would be useful in confirming the 
presence of synthesized compounds. Electronic Absorption Spectroscopy (EAS) 
would also be useful in exploring the nature of the synthesized compounds.  
 
Fluorescence studies are essential to the progress of this project. These 
studies would determine if the isomers show the same unusual photophysical 
properties exhibited by P1 as explored by Henry et al. Emission and excitation 
spectra should be examined.
14
  
 
In vitro Studies 
Before in vivo testing, these complexes require testing in in vitro samples. 
These studies would provide insight into protein motion and other subcellular 
processes. The use of {Re(CO)3}
+
 as a surrogate for {
99m
Tc(CO)3}
+
 minimizes the 
variation in physicochemical properties between fluorescence and radioactive 
imaging tests.
14
 Valliant et al. have found success applying rhenium tricarbonyl 
chelates to neural stem cells, indicating that this would be an ideal subject for in 
vitro testing.
1
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Human Subjects 
As this goal of this project is to develop an imaging agent for imaging in 
humans, the agents would need to be tested in human subjects before being used 
on a wider scale in a clinical setting. β-amyloid plaques, leukocytes, 
carbohydrates, biotin, folate, and vitamin B12 have been successfully imaged 
using 
99m
Tc chelates, suggesting the promise of  
99m
Tc tricarbonyl chelates 
synthesized with a thiazole ring.
1
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Chapter 5: In Conclusion 
 
Diagnostic medicine requires the use of radioactive imaging agents to 
view the biological vectors, with 
99m
Tc based imaging agents commonly 
preferred. {
99m
Tc(CO)3}
+
 is coordinated to single amino acid chelates to promote 
the stability of the complex. These chelates serve as a link between a biological 
vector and the radioactive metal. Rhenium is a congener of 
99m
Tc and allows 
creation of fluorescent complexes that can be used to study the properties of the 
Tc-based complexes without the harmful effects of radiation. The study of 
rhenium complexes can also provide additional insight into the coordination of 
metal tricarbonyls to bifunctional chelators. Rhenium complexes were 
coordinated to thiazole ring containing compounds to explore coordination and 
fluorescence properties. The two thiazole ring system allows coordination through 
nitrogen, sulfur, or both. The use of isomers of thiazole ring compounds provides 
insight into the various coordination methods and, while fluorescence can provide 
information regarding the photophysical properties of the rhenium based 
complexes, and ultimately, of their technetium counterparts.  
 
N1,N1-bis(thiazol-2-ylmethyl)butane-1,4-diamine, N1,N1-bis(thiazol-4,-
ylmethyl)butane-1,4-diamine, and N1,N1-bis(thiazol-5-ylmethyl)butane-1,4-
diamine were synthesized and characterized as precursors to [Re(CO)3-1,1-
bisthiazolate-(1,4)-diaminobutane]. Characterization through HPLC, 
1
H-NMR, 
and ESI-MS indicate successful synthesis of desired products of reasonable 
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purity. Additional characterization by EAS, MALDI-ToF MS, and fluorescence 
studies are required to gain further information about the properties of the 
synthesized ligands and explore their value in imaging.  
 
Completion of this project requires the synthesis of the final product, 
[Re(CO)3-1,1-bisthiazolate-(1,4)-diaminobutane], using each of the varied 
isomers. Following characterization of the product, in vitro and in vivo studies can 
be performed to explore the photophysical properties of the complexes. Ideally, 
an effective, selective imaging agent will be discovered and be applied to 
radioactive technetium complexes for clinical use in nuclear imaging.  
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